CALM: Managing Distress in Malignant Brain Cancer
The purpose of this study is to test an empirically supported psychotherapeutic intervention, Managing Cancer and Living Meaningfully (CALM), compared to treatment as usual (TAU) in those with malignant brain cancer diagnoses.
Checked against the public recordLast updated Oct 8, 2025 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Supportive Care
- Study type
- Interventional
- Phase
- Not applicable
- Sponsor
- Virginia Commonwealth University
- Interventions being studied
- Behavioral: CALM; Behavioral: Treatment as usual
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Self-reported diagnosis of brain metastasis (bMET) or a malignant primary brain tumor (PBT; specifically grade III or IV and CNS diffuse large B cell lymphomas)\* * At least 2-weeks post-surgical resection or biopsy of the brain (if applicable) * Score \> 20 on the TICS * Reported elevated depression (PHQ-9 score ≥ 10) OR death anxiety symptoms (DADDS score ≥ 15) * Ability to read, speak, and understand English * Ability to understand and the willingness to sign a written informed consent document Exclusion Criteria: * Major communication difficulties which would prohibit the psychotherapeutic interaction * Inability to meet with the interventionist via an electronic device for telehealth intervention sessions * Inability to understand and provide informed consent * Prisoners * Medical, psychological, or social condition that, in the opinion of the principal investigator, may increase the participant's risk of adverse events and/or prohibit the individual's participation in the intervention.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Virginia Commonwealth UniversityRichmond, Virginia
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 8, 2025. Always confirm current availability with the study team.